Title: Brain Industry Report – LegoChem proves its
prowess in novel drug research and development Publication: Herald Economy / Jung-Hwan Lee Date: 22 June 2015
Summary
•
LegoChem Biosciences (LCB) is a novel drug
research and development company that has generated revenue solely from its
technology since inception in 2006. •
LCB’s CEO, formerly affiliated with LG Life
Sciences, brings experiences from early drug discovery to US FDA approval. Other
competitive experts in drug synthesis also comprise LCB. •
LCB signed seven licensing and collaboration
deals for six years after inception, both globally and nationally, was listed
in the KOSDAQ in 2013, and was selected as the K-Brain company by the
government in 2014. •
The company’s short-term goal is to generate
cash flows by global out-licensing to make sure the business has enough to
survive, and eventually in the mid- and long-term, to become a global biopharmaceutical company by
combining chemical and biological drugs to make its own novel drugs to thrive.
To view the full article
(in Korean), click here ▶
About
LegoChem Biosciences
LegoChem
Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to
discovering, developing, and commercializing innovative medicines by leveraging
our chemistry expertise to make conventional biologics targeted and more potent
for the benefit of patients with diseases of high unmet medical needs. We are
advancing sustainable pipelines in therapeutic areas in antibiotics,
anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug
conjugate (PDC). | 
